MedTrace Logo

Cardiac Safety of Indacaterol

NCT01263808 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 404

Last updated 2010-12-21

No results posted yet for this study

Summary

This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.

Conditions

Interventions

DRUG

Indacaterol 150 µg

Once daily (QD) via single-dose dry powder inhaler (SDDPI)

DRUG

Indacaterol 300 µg

QD via SDDPI

DRUG

Indacaterol 600 µg

QD via SDDPI

DRUG

Placebo

QD via SDDPI

DRUG

Placebo/moxifloxacin

Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01263808 on ClinicalTrials.gov